Overview
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
Status:
Completed
Completed
Trial end date:
2005-12-01
2005-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To determine if the NMDA antagonist, CP-101,606, is effective for depressionPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
PfizerTreatments:
Antidepressive Agents
Criteria
Inclusion Criteria:- Primary DSM-IV diagnosis of MDD
Exclusion Criteria:
- Subjects with evidence or history of clinically significant hematological, renal,
endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
neurologic, or allergic disease (including drug allergies, but excluding untreated,
asymptomatic, seasonal allergies at time of dosing).